Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Myriad Genetics Inc (NASDAQ:MYGN)

19.25
Delayed Data
As of Mar 27
 -0.13 / -0.67%
Today’s Change
15.15
Today|||52-Week Range
39.74
+15.48%
Year-to-Date

Today’s Trading

Previous close19.38
Today’s open19.29
Day’s range18.59 - 19.66
Volume2,058,140
Average volume (3 months)1,475,432
Market cap$1.3B
Dividend yield--
Data as of 03/27/2017

Growth & Valuation

Earnings growth (last year)+58.33%
Earnings growth (this year)-38.90%
Earnings growth (next 5 years)-4.30%
Revenue growth (last year)+4.25%
P/E ratio22.4
Price/Sales2.98
Price/Book1.78

Competitors

 Today’s
change
Today’s
% change
AAAPAdvanced Accelerator...+0.22+0.56%
IMMUImmunomedics Inc+0.07+1.02%
QDELQuidel Corp+0.32+1.47%
--Quidel Corp-0.02-0.10%
Data as of 03/27/2017

Financials

Next reporting dateMay 9, 2017
EPS forecast (this quarter)$0.24
Annual revenue (last year)$753.8M
Annual profit (last year)$125.3M
Net profit margin16.62%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Mark C. Capone
Executive Vice President-
International Operations
Gary A. King
Corporate headquarters
Salt Lake City, Utah

Forecasts


Search for Jobs